Literature DB >> 12843350

Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.

Frank Niessen1, Thomas Hilger, Mathias Hoehn, Konstantin-A Hossmann.   

Abstract

BACKGROUND AND
PURPOSE: Thrombin-induced clots used in experimental thromboembolic stroke differ from clots forming spontaneously under clinical conditions. We investigated whether this difference influences the efficacy and outcome of thrombolytic treatment.
METHODS: In rats, the middle cerebral artery was occluded by intracarotid injection of fibrin-rich clots, prepared either according to established methods by adding thrombin to freshly drawn arterial blood or by spontaneous coagulation. The mechanical properties of clots were determined in vitro by elasticity and plasticity tests. One hour after embolism, thrombolysis was started by intra-arterial application of recombinant tissue plasminogen activator (rtPA) (10 mg/kg). Treatment efficacy was monitored by MR measurements of blood perfusion, apparent diffusion coefficient (ADC), T2 relaxation time and blood-brain barrier permeability, and by pictorial measurements of ATP and pH.
RESULTS: Thrombin-induced clots were classified as elastic, and spontaneously forming clots were classified as plastic. Middle cerebral artery embolism with thrombin-induced or spontaneously forming clots led to similar reduction of perfusion and ADC, but rtPA treatment efficacy differed greatly. In the spontaneously forming clot group, blood perfusion returned to or above control within 2 hours, ADC and ATP normalized, tissue pH exhibited alkalosis, and T2 and blood-brain barrier permeability did not change. In the thrombin-induced clot group, in contrast, blood reperfusion was delayed, ADC and ATP remained reduced, tissue pH was acidic, and edema developed, as reflected by increased T2 and blood-brain barrier permeability.
CONCLUSIONS: rtPA-induced thrombolysis promotes rapid reperfusion and tissue recovery in animals embolized with spontaneously forming clots but not in those embolized with thrombin-induced clots. This difference is explained by the different mechanical and possibly molecular consequences of clot preparation and must be considered for the interpretation of thrombolysis experiments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843350     DOI: 10.1161/01.STR.0000080941.73934.30

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

1.  Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.

Authors:  Christy K Holland; Sampada S Vaidya; Saurabh Datta; Constantin-C Coussios; George J Shaw
Journal:  Thromb Res       Date:  2007-09-14       Impact factor: 3.944

2.  Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.

Authors:  Kama Z Guluma; Paul A Lapchak
Journal:  Brain Res       Date:  2010-07-29       Impact factor: 3.252

Review 3.  Enhanced spontaneous thrombolysis: a new therapeutic challenge.

Authors:  I B Kovacs; D A Gorog; J Yamamoto
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 4.  Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia.

Authors:  David W Howells; Michelle J Porritt; Sarah S J Rewell; Victoria O'Collins; Emily S Sena; H Bart van der Worp; Richard J Traystman; Malcolm R Macleod
Journal:  J Cereb Blood Flow Metab       Date:  2010-05-19       Impact factor: 6.200

5.  Presence of multi-segment clot sign on dynamic CT angiography: a predictive imaging marker of recanalisation and good outcome in acute ischaemic stroke patients.

Authors:  Feina Shi; Zhicai Chen; Xiaoxian Gong; Meixia Zhang; David S Liebeskind; Min Lou
Journal:  Eur Radiol       Date:  2018-03-13       Impact factor: 5.315

6.  Control of cerebral ischemia with magnetic nanoparticles.

Authors:  Jie-Min Jia; Praveen D Chowdary; Xiaofei Gao; Bo Ci; Wenjun Li; Aditi Mulgaonkar; Erik J Plautz; Gedaa Hassan; Amit Kumar; Ann M Stowe; Shao-Hua Yang; Wei Zhou; Xiankai Sun; Bianxiao Cui; Woo-Ping Ge
Journal:  Nat Methods       Date:  2016-12-12       Impact factor: 28.547

7.  Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia.

Authors:  Sophie Gautier; Thavarak Ouk; Olivier Petrault; Jacques Caron; Régis Bordet
Journal:  Br J Pharmacol       Date:  2009-02-04       Impact factor: 8.739

8.  Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".

Authors:  Jason M Meunier; Evan Wenker; Christopher J Lindsell; George J Shaw
Journal:  Acad Emerg Med       Date:  2013-05       Impact factor: 3.451

9.  A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia.

Authors:  Yu-Yo Sun; Chia-Yi Kuan
Journal:  J Vis Exp       Date:  2015-08-18       Impact factor: 1.355

10.  Clot injection technique affects thrombolytic efficacy in a rat embolic stroke model: implications for translaboratory collaborations.

Authors:  Marilena Marinescu; James Bouley; Juyu Chueh; Marc Fisher; Nils Henninger
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-15       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.